A5013860972- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Medical Imaging and Pathology Studies
- Metastasis and carcinoma case studies
- Cancer Research and Treatments
Baylor College of Medicine
2022
Abstract Purpose: We report the results of a phase II, randomized, window-of-opportunity trial neoadjuvant durvalumab versus plus tremelimumab followed by surgery in patients with resectable malignant pleural mesothelioma (MPM; NCT02592551). Patients and Methods: The primary objective was alteration intratumoral CD8/regulatory T cell (Treg) ratio after combination immune checkpoint blockade (ICB) therapy. Secondary exploratory objectives included other changes tumor microenvironment,...
<div>AbstractPurpose:<p>We report the results of a phase II, randomized, window-of-opportunity trial neoadjuvant durvalumab versus plus tremelimumab followed by surgery in patients with resectable malignant pleural mesothelioma (MPM; NCT02592551).</p>Patients and Methods:<p>The primary objective was alteration intratumoral CD8/regulatory T cell (Treg) ratio after combination immune checkpoint blockade (ICB) therapy. Secondary exploratory objectives included other...
<p>Supplementary Figure 4. Frequencies of other immune and stromal cell compositions before after ICB.</p>
<p>Supplementary Figure 9. Alteration of naïve T (Tnaive) and stem cell-like memory (Tscm) cells in PBMCs BMMCs.</p>
<div>AbstractPurpose:<p>We report the results of a phase II, randomized, window-of-opportunity trial neoadjuvant durvalumab versus plus tremelimumab followed by surgery in patients with resectable malignant pleural mesothelioma (MPM; NCT02592551).</p>Patients and Methods:<p>The primary objective was alteration intratumoral CD8/regulatory T cell (Treg) ratio after combination immune checkpoint blockade (ICB) therapy. Secondary exploratory objectives included other...
<p>Supplementary Figure 4. Frequencies of other immune and stromal cell compositions before after ICB.</p>
<p>Supplementary Methods</p>
<p>Supplementary Figure 7. Characterization of CD57+ T cell populations in tumor and PBMCs from MPM patients.</p>
<p>Supplementary Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram.</p>
<p>Supplementary Figure 10. Presence of follicular helper T cells in CD57(+) cells</p>
<p>Supplementary Figure 8. Phenotyping of circulating CD8 and CD4 T cells in MPM patients that received neoadjuvant ICB</p>
<p>Supplementary Figure 7. Characterization of CD57+ T cell populations in tumor and PBMCs from MPM patients.</p>
<p>Supplementary Figure 6. Germinal center containing Ki67(+) B cells and CD68(+) fDC-like cell meshwork in mature tertiary lymphoid structure.</p>
<p>Supplementary Figure 5. Overall survival of historical MPM cohorts</p>
<p>Supplementary Figure 8. Phenotyping of circulating CD8 and CD4 T cells in MPM patients that received neoadjuvant ICB</p>
<p>Supplementary Methods</p>